Correlation Between Cadrenal Therapeutics, and Cingulate Warrants

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Cingulate Warrants at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Cingulate Warrants into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Cingulate Warrants, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Cingulate Warrants and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Cingulate Warrants. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Cingulate Warrants.

Diversification Opportunities for Cadrenal Therapeutics, and Cingulate Warrants

-0.32

Correlation Coefficient

Cadrenal Therapeutics,  Cingulate Warrants

Very good diversification

The 3 months correlation between Cadrenal and Cingulate is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Cingulate Warrants in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cingulate Warrants and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Cingulate Warrants. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cingulate Warrants has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Cingulate Warrants go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Cingulate Warrants

Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to under-perform the Cingulate Warrants. But the stock apears to be less risky and, when comparing its historical volatility, Cadrenal Therapeutics, Common is 3.7 times less risky than Cingulate Warrants. The stock trades about -0.3 of its potential returns per unit of risk. The Cingulate Warrants is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  4.49  in Cingulate Warrants on September 12, 2024 and sell it today you would lose (0.86) from holding Cingulate Warrants or give up 19.15% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	95.24%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Cingulate Warrants

Cadrenal Therapeutics,

Risk-Adjusted Performance

5 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Cingulate Warrants

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cingulate Warrants has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly weak technical and fundamental indicators, Cingulate Warrants may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Cadrenal Therapeutics, and Cingulate Warrants

The main advantage of trading using opposite Cadrenal Therapeutics, and Cingulate Warrants positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Cingulate Warrants can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cingulate Warrants will offset losses from the drop in Cingulate Warrants' long position.

The idea behind Cadrenal Therapeutics, Common and Cingulate Warrants pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.